KEYTRUDA Merck Sharp & Dohme (Australia) Pty Ltd
Product name
KEYTRUDA
Accepted date
Apr-2024
Active ingredients
pembrolizumab
Proposed indication
Indicated for the treatment of patients with primary advanced or recurrent endometrial carcinoma.
Application type
C (new indication)
Publication date
Apr-2024